Plasma insulin-like growth factor-I, CA-125, estrogen, and progesterone in women with leiomyomas

• Published in: Fertility and sterility Vol. 61; no. 4; pp. 617 - 621
• Main Authors: Dawood, M. Yusoff, Khan-Dawood, Firyal S.
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier Inc 01.04.1994; Elsevier Science
• Subjects: Adult; Antigens, Tumor-Associated, Carbohydrate - blood; Biological and medical sciences; CA-125; Estradiol - blood; estrogen; Estrogens - blood; Estrone - blood; Female; Female genital diseases; Follicular Phase - blood; Gynecology. Andrology. Obstetrics; Humans; insulin-like growth factor; Insulin-Like Growth Factor I - metabolism; Leiomyoma; Leiomyoma - blood; Luteal Phase - blood; Medical sciences; Middle Aged; progesterone; Progesterone - blood; Tumors; Uterine Neoplasms - blood; Leiomyoma; CA-125; estrogen; insulin-like growth factor; progesterone; Human; Pathophysiology; Somatomedin C; Cytokine; Estrogen; Biological marker; Smooth muscle; Tumoral marker; Ovarian hormone; Female genital diseases; Progestagen; Uterus; Polypeptide; Uterine diseases; Benign neoplasm; Hormonal investigation; Progesterone; Sex steroid hormone; Growth factor
• ISSN: 0015-0282; 1556-5653
• DOI: 10.1016/S0015-0282(16)56635-7

To determine plasma levels of insulin-like growth factor-I (IGF-I), CA-125, estrone (E1), E2, and P in women with uterine leiomyomas compared with normal women. Women with leiomyomas were compared with normal women (control). University Department of Obstetrics and Gynecology. Fifty-one premenopausal women with uterine myomas>14weeks gestation and 30 normal fertile women (controls) were studied. Peripheral blood samples were obtained before myomectomy or hysterectomy and during the nonmenstruating phase in the controls. Plasma levels of E1, E2, P, CA-125, and IGF-I were determined by specific and sensitive RIAs and immunoradiometric assays. Plasma IGF-I levels were 2,006±185mU/mL (mean±SEM, n=35) and 2,335±287mU/mL (n=16) in women with leiomyomas during the follicular and luteal phases, respectively, whereas the corresponding values for normal women were 1,702±120 (n=30) and 1,774±239mU/mL (n=30). Similarly, plasma CA-125 levels were unchanged in women with leiomyomas (myomas: 18.8±2.4, 21.5±3.7 U/mL; normal: 15.9±1.5, 15.8±1.3 U/mL during follicular and luteal phases, respectively). Women with leiomyomas had plasma El, E2, and P levels during the follicular phase (91.9±11.5pg/mL; conversion factor to SI unit, 3.699; 94.6±19.0pg/mL; conversion factor to SI unit, 3.671; and 1.5±0.4ng/mL; conversion factor to SI unit, 3.180, respectively) and the luteal phase (105.8±11.2pg/mL; conversion factor to SI unit, 3.699; 128.7±24.8pg/mL; conversion factor to SI unit, 3.671; and 9.6±1.6ng/mL; conversion factor to SI unit, 3.180) similar to normal women. Plasma levels of IGF-I, CA-125, E1, E2, and P are normal in women with leiomyomas.